Disease of aging
Hearing Loss (Presbycusis)
Last updated Sat May 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
RCT evidence— ACHIEVE showed slowed cognitive decline in high-risk subgroup
Why it’s a longevity priority
The 2024 Lancet Commission identified hearing loss as the largest single modifiable contributor to dementia risk worldwide. Mechanisms likely include:
- Increased cognitive load from poor signal.
- Social isolation and reduced cognitive stimulation.
- Possible direct neurodegenerative pathway.
- Higher fall risk.
The ACHIEVE trial (2023)
Randomised 977 older adults with hearing loss to hearing intervention (audiologist + hearing aids + counselling) vs health-education control, 3-year follow-up. In the at-risk ARIC cohort embedded in the trial, hearing intervention slowed cognitive decline by ~48% compared to control. Effect in the general healthy-volunteer cohort was smaller.
Beyond dementia
- Falls (untreated hearing loss roughly triples fall risk).
- Social withdrawal and depression.
- Tinnitus.
- Reduced quality of life and relationship strain.
Practical action
- Get tested. Most insurance won’t cover hearing aids, but the test is widely available.
- Treat early. Once hearing loss is moderate, the cortical reorganisation may make adaptation harder.
- OTC hearing aids (US, since 2022) have dramatically lowered cost for mild-moderate presbycusis.
- Protect remaining hearing: noise exposure (concerts, headphones, power tools) accelerates further loss.
Related entries
References
- Lin, F. R. et al. Hearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss (ACHIEVE). Lancet 402, 786–797 (2023).